Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.

Autor: Henderson R; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Anasti K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Manne K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Stalls V; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Saunders C; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Bililign Y; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Williams A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Bubphamala P; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Montani M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Kachhap S; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Li J; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Jaing C; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Newman A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Cain DW; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Lu X; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Venkatayogi S; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Berry M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Wagh K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Korber B; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.; The New Mexico Consortium, Los Alamos, NM, USA., Saunders KO; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.; Department of Surgery, Duke University Medical Center, Durham, NC, USA., Tian M; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.; Department of Genetics, Harvard Medical School, Boston, MA, USA., Alt F; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.; Department of Genetics, Harvard Medical School, Boston, MA, USA., Wiehe K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Acharya P; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.; Department of Surgery, Duke University Medical Center, Durham, NC, USA.; Department of Biochemistry, Duke University, Durham, NC, USA., Alam SM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA.; Department of Pathology, Duke University School of Medicine, Durham, NC, USA., Haynes BF; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA. barton.haynes@duke.edu.; Department of Immunology, Duke University Medical Center, Durham, NC, USA. barton.haynes@duke.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Nov 03; Vol. 15 (1), pp. 9503. Date of Electronic Publication: 2024 Nov 03.

Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.

Autor: Rahman MA; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Bissa M; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Scinto H; Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Howe SE; Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sarkis S; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ma ZM; California National Primate Research Center, University of California, Davis, Davis, USA., Gutowska A; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jiang X; Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA., Luo CC; Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA., Schifanella L; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Moles R; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Silva de Castro I; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Basu S; United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., N'guessan KF; United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Williams LD; Center for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA., Becerra-Flores M; New York University School of Medicine, NYU Langone Health, New York, NY, USA., Doster MN; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hoang T; Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Choo-Wosoba H; Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Woode E; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sui Y; Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Tomaras GD; Center for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA., Paquin-Proulx D; United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Rao M; United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Talton JD; Alchem Laboratories Corporation, Alachua, FL, USA., Kong XP; Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA., Zolla-Pazner S; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, NY, New York, USA., Cardozo T; New York University School of Medicine, NYU Langone Health, New York, NY, USA., Franchini G; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. franchig@mail.nih.gov., Berzofsky JA; Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. berzofsj@mail.nih.gov.

Publikováno v: Nature communications [Nat Commun] 2024 Oct 22; Vol. 15 (1), pp. 9102. Date of Electronic Publication: 2024 Oct 22.

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.

Autor: Kenny A; Department of Biostatistics, University of Washington, Seattle, WA, USA., van Duijn J; Janssen Vaccines & Prevention BV, Leiden, the Netherlands., Dintwe O; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Heptinstall J; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA., Burnham R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Sawant S; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA., Zhang L; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA., Mielke D; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA., Khuzwayo S; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Omar FL; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Stanfield-Oakley S; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA., Keyes T; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA., Dunn B; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA., Goodman D; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA., Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Zou R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hural J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hyrien O; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Juraska M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Luedtke A; Department of Statistics, University of Washington, Seattle, WA, USA., van der Laan L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Statistics, University of Washington, Seattle, WA, USA., Giorgi EE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Magaret C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Pattacini L; Janssen Vaccines & Prevention BV, Leiden, the Netherlands., van de Kerkhof T; Janssen Vaccines & Prevention BV, Leiden, the Netherlands., Korber B; Los Alamos National Laboratory, Los Alamos, NM, USA; New Mexico Consortium, Los Alamos, NM, USA., Willems W; Janssen Research & Development BE, Beerse, Belgium., Fisher LH; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Schuitemaker H; Janssen Vaccines & Prevention BV, Leiden, the Netherlands., Swann E; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Pau MG; Janssen Infectious Diseases BV, Beerse, Belgium., Buchbinder S; San Francisco Department of Public Health, San Francisco, CA, USA., Tomaka F; Janssen Research & Development, LLC, Titusville, NJ, USA., Nijs S; Janssen Infectious Diseases BV, Beerse, Belgium., Lavreys L; Janssen Infectious Diseases BV, Beerse, Belgium., Gelderblom HC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, 98195, USA., Mngadi K; The Aurum Institute, Johannesburg, South Africa., Gray GE; South African Medical Research Council, Cape Town, South Africa., Borducchi E; Center for Virology & Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA., Hendriks J; Janssen Vaccines & Prevention BV, Leiden, the Netherlands., Seaton KE; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA., Zolla-Pazner S; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Barouch DH; Center for Virology & Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, USA., Ferrari G; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Andersen-Nissen E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Stieh DJ; Janssen Vaccines & Prevention BV, Leiden, the Netherlands., Tomaras GD; Center for Human Systems Immunology, Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Durham, NC, USA; Department of Integrative Immunobiology, Duke University, Durham, NC, USA. Electronic address: georgia.tomaras@duke.edu., Gilbert PB; Department of Biostatistics, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: pgilbert@fredhutch.org.

Publikováno v: EBioMedicine [EBioMedicine] 2024 Oct; Vol. 108, pp. 105320. Date of Electronic Publication: 2024 Sep 04.

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines.

Autor: Schwarzmüller M; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Lozano C; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Schanz M; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Abela IA; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland., Grosse-Holz S; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Epp S; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Curcio M; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Greshake J; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Rusert P; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Huber M; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland., Kouyos RD; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland., Günthard HF; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland., Trkola A; Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland. Electronic address: trkola.alexandra@virology.uzh.ch.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Sep 17; Vol. 5 (9), pp. 101702. Date of Electronic Publication: 2024 Aug 30.

Acceptability, facilitators, and barriers to a hypothetical HIV vaccine in the pre-exposure prophylaxis era.

Autor: Richterman A; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn Leonard Davis Institute of Health Economics, Philadelphia, PA, USA., O'Brien C; Mixed Methods Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA., Ghadimi F; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Sumners E; The COLOURS Organization, Philadelphia, PA, USA., Ford A; The COLOURS Organization, Philadelphia, PA, USA., Houston N; Bebashi-Transition to Hope, Philadelphia, PA, USA., Tate S; Bebashi-Transition to Hope, Philadelphia, PA, USA., Aitcheson N; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn Leonard Davis Institute of Health Economics, Philadelphia, PA, USA., Nkwihoreze H; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Jemmott JB 3rd; Annenberg School of Communication, University of Pennsylvania, Philadelphia, PA, USA.; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA., Momplaisir F; Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn Leonard Davis Institute of Health Economics, Philadelphia, PA, USA.

Publikováno v: AIDS care [AIDS Care] 2024 Nov; Vol. 36 (11), pp. 1563-1569. Date of Electronic Publication: 2024 Jul 04.